Latest News and Press Releases

PRINCETON, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position...

PRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire...

PRINCETON, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the launch of Synchrogenix™ Writer, a new regulatory SaaS product that expedites the...

新泽西州普林斯顿, Sept. 23, 2021 (GLOBE NEWSWIRE) -- 作为生物模拟领域的全球领军者，Certara（纳斯达克股票代码：CERT）今天宣布获得美国食品药品监督管理局 (FDA) 的研究基金，以验证并扩展用于评估虚拟生物等效性 (VBE) 的生物模拟模型，进而有助于促进更安全、更快速且更具性价比的仿制药开发。 生物等效性 (BE)...

PRINCETON, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical...

PRINCETON, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S. Food and Drug...

PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common...

PRINCETON, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its...

PRINCETON, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of...

PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the...